Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Maxcyte Inc.
Headquarters: Rockville, MD, United States of America
Website: http://www.maxcyte.com
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Maher Masoud
Number Of Employees: 114
Enterprise Value: $300,448,709
PE Ratio: -7.29
Exchange/Ticker 1: LSE:MXCT
Exchange/Ticker 2: NASDAQ:MXCT
Latest Market Cap: $306,207,093
BioCentury | Oct 11, 2024
Management Tracks
Flagship takes on a third managing partner
Plus: New CEOs at Wheeler, Abalos, Oncovita, Syneos and Calluna, and updates from Phase, Ziphius and more
BioCentury | Dec 13, 2023
Management Tracks
Magargee named CEO of Genentech
Plus: Garay steps down Moderna’s head of commercial and updates from MaxCyte, Aiolos, Corsair, BioXcel and more
BioCentury | Apr 14, 2022
Management Tracks
Murphy resigns from MaxCyte
Plus AbbVie’s Severino becomes CEO-partner at Flagship, and updates from Ikena, Fusion, Nimbus and more
BioCentury | Mar 28, 2022
Management Tracks
Asif Ali to join Protagonist as CFO
Plus new CMO at Avenge Bio, new CEO at
BioCentury | Mar 11, 2022
Management Tracks
Sandrock joins board at Atalanta
Plus Imbria staffs C-suite and updates from Berkeley Lights, Akouos and more
BioCentury | Nov 4, 2021
Management Tracks
Hoelscher to retire from Horizon
Plus: Ipsen, MaxCyte, Cara, Fusion and more
BioCentury | Jul 30, 2021
Finance
July a busy month for IPOs as new quintet lands on NASDAQ
Friday’s fresh paper made July NASDAQ’s busiest IPO month this year, with 15 companies debuting
BioCentury | Oct 17, 2020
Management Tracks
Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more
Luciano Rossetti will retire at year-end from Merck KGaA (Xetra:MRK) after a six-year tenure as global head of R&D for the healthcare business sector. Rossetti’s
BioCentury | Oct 14, 2020
Management Tracks
Anderson joining Sofinnova Partners to bridge European biotechs to public markets
Veteran investor to manage French firm’s crossover fund as IPOs continue to price at record pace in 2020
BioCentury | Sep 12, 2020
Management Tracks
New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more
It’s been a busy week for C4 Therapeutics Inc., which hired a new CEO and filed to go public. Andrew Hirsch is joining the protein degradation company from Agios
Items per page:
1 - 10 of 52